Iron Man

FOR RESEARCH PURPOSES ONLY

Iron man is a research peptide and not approved by any medical board.

Iron Man is an injectable peptide which can be used to promote healing, enhance range of motion in cases of injury, or reduce pain in case of injury by reducing inflammation. Iron Man is different from other repair factors (growth hormone, IGF-1), because it promotes endothelial and keratinocyte migration. It also does not bind to the extracellular matrix and has a very low molecular weight. Because of this it can travel long distances through the tissues in the human body.

One of Iron Man’s key mechanisms of action is its ability to regulate the cell-building protein – Actin. Of the thousands of proteins present within human cells, actin represents roughly 10% of the total. It is thus a vital component of cell structure and movement.

While Iron Man can be remarkably effective administered alone, one can experience better results when it is taken together with GH.

Alternately, compared to using Iron Man alone, the healing effect can be improved by combining Iron Man with a GHRP (such as GHRP-2, GHRP-6, ipamorelin, or hexarelin), or a GHRP / Mod GRF stack.

Of those two approaches, from results I presently believe the Iron Man / GH stack to be the more effective.

Iron Man is typically provided as lyophilized (freeze-dried) powder in vials of 2.0 mg. A convenient amount of sterile or bacteriostatic water will be added, such as 1.0 mL. In the most common dosing protocol, the entire vial is taken at one time. If taking the entire vial, the entire amount will be drawn into a syringe, typically an insulin syringe, and injected. Injection may be subcutaneous, intramuscular, or intravenous, according to personal preference.

The most common dosing protocol is to take 2.0 or 2.5 mg of Iron Man twice per week for four to six weeks, and then reduce to a lower dosing rate such as once or twice per month for maintenance.

 

All peptides are sold as research peptides